Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | STAMBP | O95630 | 1/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066391 | 0.88 | NTRK1 (0.50) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2065650 | 0.88 | NTRK1 (0.50) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2065873 | 0.84 | NTRK1 (0.49) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2066253 | 0.82 | NTRK1 (0.47) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2066442 | 0.81 | NTRK1 (0.50) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2066842 | 0.81 | NTRK1 (0.44) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2065662 | 0.81 | NTRK1 (0.44) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2067762 | 0.80 | NTRK1 (0.47) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2064849 | 0.79 | NTRK1 (0.43) | NTRK1KDRJAK3BTKITK | |
| SCHEMBL2065601 | 0.79 | NTRK1 (0.45) | NTRK1KDRJAK3BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099794-B1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148400-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2008079873-A2 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048581-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | ERBB2, TEC, TTBK1 | NTRK1 327/4885KDR 672/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.